CN101711236B - 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 - Google Patents

表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 Download PDF

Info

Publication number
CN101711236B
CN101711236B CN2008800175988A CN200880017598A CN101711236B CN 101711236 B CN101711236 B CN 101711236B CN 2008800175988 A CN2008800175988 A CN 2008800175988A CN 200880017598 A CN200880017598 A CN 200880017598A CN 101711236 B CN101711236 B CN 101711236B
Authority
CN
China
Prior art keywords
purposes
compound
pharmaceutical composition
oxide
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800175988A
Other languages
English (en)
Chinese (zh)
Other versions
CN101711236A (zh
Inventor
H·V·维克斯特罗姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
NSAB Filial af Neurosearch Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NSAB Filial af Neurosearch Sweden AB filed Critical NSAB Filial af Neurosearch Sweden AB
Publication of CN101711236A publication Critical patent/CN101711236A/zh
Application granted granted Critical
Publication of CN101711236B publication Critical patent/CN101711236B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008800175988A 2007-04-12 2008-04-11 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 Expired - Fee Related CN101711236B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0700893-1 2007-04-12
SE0700893 2007-04-12
PCT/SE2008/050414 WO2008127188A1 (en) 2007-04-12 2008-04-11 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

Publications (2)

Publication Number Publication Date
CN101711236A CN101711236A (zh) 2010-05-19
CN101711236B true CN101711236B (zh) 2012-10-31

Family

ID=39864178

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800175988A Expired - Fee Related CN101711236B (zh) 2007-04-12 2008-04-11 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物

Country Status (19)

Country Link
US (1) US9139525B2 (enExample)
EP (1) EP2146961B1 (enExample)
JP (1) JP5393654B2 (enExample)
CN (1) CN101711236B (enExample)
AU (1) AU2008239841B2 (enExample)
BR (1) BRPI0810161A2 (enExample)
CA (1) CA2683719C (enExample)
CY (1) CY1115337T1 (enExample)
DK (1) DK2146961T3 (enExample)
ES (1) ES2458592T3 (enExample)
HR (1) HRP20140380T1 (enExample)
IL (1) IL201401A (enExample)
MX (1) MX2009011020A (enExample)
NZ (1) NZ580856A (enExample)
PL (1) PL2146961T3 (enExample)
PT (1) PT2146961E (enExample)
RU (1) RU2470013C2 (enExample)
SI (1) SI2146961T1 (enExample)
WO (1) WO2008127188A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2010058019A1 (en) * 2008-11-24 2010-05-27 Nsab, Filial Af Neurosearch Sweden Ab, Sverige 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
JP2020532517A (ja) 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018475A2 (en) * 1991-04-17 1992-10-29 The Upjohn Company Substituted phenylazacycloalkanes as cns agents
CN1420870A (zh) * 1999-12-22 2003-05-28 A·卡尔松研究股份公司 新的多巴胺神经传递调节剂
WO2003064393A1 (en) * 2002-02-01 2003-08-07 Axon Biochemicals B.V. Thio-carbostyril derivative, its n-oxides and the n-oxides of aripiprazole
WO2007023141A1 (en) * 2005-08-22 2007-03-01 Solvay Pharmaceuticals B.V. N-oxides as prodrugs of piperazine & piperidine derivatives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1217296A (en) 1917-01-11 1917-02-27 Lewis A Peckham Shock-absorber.
US2813098A (en) 1955-08-16 1957-11-12 Upjohn Co 3-methoxy-n-methylmorphinan n-oxide
US2813097A (en) 1955-08-16 1957-11-12 Upjohn Co 3-hydroxy-n-methylmorphinan-n-oxide
US3131185A (en) 1959-03-18 1964-04-28 Orsymonde Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters
BE638369A (enExample) 1962-10-10
CH481124A (de) 1966-09-21 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IL112099A (en) * 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
US6121259A (en) * 1998-11-23 2000-09-19 Sepracor Inc. Olanzapine-N-oxide compositions and methods
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
MXPA06013941A (es) * 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
CA2569843A1 (en) 2004-06-08 2005-12-22 A. Carlsson Research Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
WO2006020573A2 (en) * 2004-08-11 2006-02-23 Barbeau Donald L Noncardiotoxic pharmaceutical compounds
ES2659577T3 (es) * 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
UA96756C2 (en) * 2006-05-02 2011-12-12 Эббот Хелскеа Продактс Б.В. N-oxides of pyridylmethylpiperazine and -piperidine derivatives
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130203886A1 (en) * 2010-03-05 2013-08-08 Nileshkumar Prakash Kukalyekar Process for the production of an uhmwpe article
NZ608120A (en) * 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) * 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
MX2015003812A (es) * 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
US20150209346A1 (en) * 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018475A2 (en) * 1991-04-17 1992-10-29 The Upjohn Company Substituted phenylazacycloalkanes as cns agents
CN1420870A (zh) * 1999-12-22 2003-05-28 A·卡尔松研究股份公司 新的多巴胺神经传递调节剂
WO2003064393A1 (en) * 2002-02-01 2003-08-07 Axon Biochemicals B.V. Thio-carbostyril derivative, its n-oxides and the n-oxides of aripiprazole
WO2007023141A1 (en) * 2005-08-22 2007-03-01 Solvay Pharmaceuticals B.V. N-oxides as prodrugs of piperazine & piperidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SONESSON C.等.SUBSTITUTED (S)-PHENYLPIPERIDINES AND RIGID CONGENERS AS PREFERENTIAL DOPAMINE AUTORECEPTOR ANTAGONISTS: SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS..《Journal of Medicinal Chemistry》.1994,第37卷(第17期),全文. *

Also Published As

Publication number Publication date
CA2683719C (en) 2015-07-14
ES2458592T3 (es) 2014-05-06
PT2146961E (pt) 2014-04-30
IL201401A0 (en) 2010-05-31
EP2146961A1 (en) 2010-01-27
JP5393654B2 (ja) 2014-01-22
NZ580856A (en) 2011-11-25
RU2470013C2 (ru) 2012-12-20
BRPI0810161A2 (pt) 2014-12-30
SI2146961T1 (sl) 2014-08-29
US9139525B2 (en) 2015-09-22
EP2146961B1 (en) 2014-01-29
AU2008239841A1 (en) 2008-10-23
CN101711236A (zh) 2010-05-19
PL2146961T3 (pl) 2014-09-30
MX2009011020A (es) 2009-10-30
US20100105736A1 (en) 2010-04-29
RU2009141300A (ru) 2011-05-20
DK2146961T3 (da) 2014-04-28
WO2008127188A1 (en) 2008-10-23
IL201401A (en) 2015-10-29
JP2010523651A (ja) 2010-07-15
EP2146961A4 (en) 2011-08-03
HRP20140380T1 (hr) 2014-08-15
AU2008239841B2 (en) 2013-07-18
CY1115337T1 (el) 2017-01-04
CA2683719A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
JP5393654B2 (ja) 改善された心血管副作用プロフィールを呈する、ドーパミン受容体安定剤／調節剤のｎ−オキシド誘導体及び／又はジ−ｎ−オキシド誘導体
AU2021404159A9 (en) Cannabinoid derivatives as pharmaceutically active compounds and method of preparation thereof
US12312328B2 (en) Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
HUE028391T2 (en) Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands
CN106478502B (zh) 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
CN111432810B (zh) 硝酸氨基金刚烷酯化合物和它们用于治疗cns病症的用途
CN104470911B (zh) 氨基甲酸酯/脲衍生物
CA3232914A1 (en) Lsd derivatives, synthesis & method for treatment of diseases and disorders
CN107382870A (zh) N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
WO2008042755A2 (en) Inhibitors of cognitive decline
ES2407140T3 (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica
CN103787954B (zh) 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途
WO2022129909A1 (en) Cannabinoid derivatives as pharmaceutically active compounds and method of preparation thereof
JP5486008B2 (ja) １‐ブチル‐２‐ヒドロキシアラルキルピペラジン誘導体およびその抗鬱剤としての使用
EP2128137A1 (en) Selective m4 receptor antagonist and its medical use
EP4043436A1 (en) Magl inhibitor, preparation method therefor and use thereof
CN103193857B (zh) 止泻木生物碱衍生物及其用途
CN103121970B (zh) 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
CN101190914B (zh) 16位取代双功能团石杉碱乙衍生物、其制备方法及其用途
HK40072310A (en) Magl inhibitor, preparation method therefor and use thereof
JP2006316064A (ja) ３（２ｈ）−ピリダジノン誘導体及びこれら化合物の使用
CN107043361A (zh) 治疗心绞痛的化合物、制备方法及用途
HK1069818B (en) Process for obtainment of enantiomers-of n-(2,6-dimethylphenyl)-1-propyl-2- piperidinocarboxamide; process for obtainment of non-racemic mixtures between the enantiomers of n-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide; non racemic mixtures of enantiomers of n-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide; pharmaceuticals compositions comprising said non-racemic mixtures of enantiomers of n-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide
HK1069818A1 (en) Process for obtainment of enantiomers-of n-(2,6-dimethylphenyl)-1-propyl-2- piperidinocarboxamide; process for obtainment of non-racemic mixtures between the enantiomers of n-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide; non racemic mixtures of enantiomers of n-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide; pharmaceuticals compositions comprising said non-racemic mixtures of enantiomers of n-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: EVAC+CHAIR INTERNATIONAL LTD.

Free format text: FORMER OWNER: NSAB AF NEUROSEARCH SWEDEN AB

Effective date: 20130731

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130731

Address after: La Perth, Switzerland

Patentee after: IVak International Limited

Address before: Denmark and Rupp

Patentee before: Nsab Af Neurosearch Sweden AB

C56 Change in the name or address of the patentee

Owner name: TEVA PHARMACEUTICAL INTERNATIONAL LTD.

Free format text: FORMER NAME: EVAC+CHAIR INTERNATIONAL LTD.

CP03 Change of name, title or address

Address after: Switzerland Jonathan

Patentee after: TEVA PHARMACEUTICALS INTERNATIONAL GMBH

Address before: La Perth, Switzerland

Patentee before: IVak International Limited

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121031

Termination date: 20180411

CF01 Termination of patent right due to non-payment of annual fee